Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.
300452.SZ
Shenzhen Stock Exchange12.05
CNY
-0.42
- -
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.
300452.SZ
(Shenzhen Stock Exchange)
Recent
price
12.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Anhui Sunhere Pharmaceutical Excipients Co., Ltd. specializes in the research, development, production, and sale of pharmaceutical excipients. The company manufactures a diverse range of excipients including hypromellose (hydroxypropyl methylcellulose, HPMC) used as film-forming agents and emulsifiers; low-substituted hydroxypropyl cellulose (LHPC); maize starch and corn starch serving as tablet and capsule diluents and disintegrants; magnesium stearate as a lubricant excipient; microcrystalline cellulose; polyacrylic resin IV for gastric-soluble coatings; povidone as a solubility enhancer and film former; silicon dioxide as a flow agent; and additional excipients such as stearic acid, coating powders, resins, and food additives. The company also provides technical support services including formulation development, quality control, stability testing, and customized excipient solutions. Anhui Sunhere primarily serves the pharmaceutical industry across China and exports internationally. Founded in 2001 and headquartered in Huainan, Anhui Province, it is one of China's largest excipient manufacturers and a national R&D base recognized as a high-tech corporation in Anhui Province. In recent developments, Anhui Sunhere has undertaken a strategic capital increase of 92 million yuan into its wholly-owned subsidiary, Hefei Sunhere Pharmaceutical Technology Co., Ltd., to support the construction of a new R&D center and production base in Hefei's High-tech Zone, aiming to enhance innovation and production capacity. The company is actively participating in land acquisition for this project and continuing its expansion of research and production facilities. Additionally, Anhui Sunhere has acquired a 52% stake in Qufu Tianli Medical Supplements to broaden its business scope. The company has also gained recognition for breaking technological monopolies in domestic excipients, challenging Japanese market dominance through innovation. Shareholders plan to reduce their holdings by up to 3% between late 2025 and early 2026. Anhui Sunhere maintains leadership in excipient manufacturing for solid dosage forms in China and is positioned for continued growth through enhanced R&D and strategic investments. Anhui Sunhere operates within the pharmaceutical excipients industry segment, targeting pharmaceutical companies requiring base materials for solid oral dosage forms and other pharmaceutical products. Its product portfolio focuses heavily on cellulose derivatives, starch derivatives, and other performance-enhancing excipients. The company holds various national and provincial innovation awards and participates in the executive director role of the China Pharmaceutical Excipients industry association, underlining its industry influence. This comprehensive product offering and ongoing strategic facility expansion underline Anhui Sunhere Pharmaceutical Excipients Co., Ltd.'s commitment to technological advancement and market leadership in China’s pharmaceutical excipient manufacturing sector. The company’s operations concentrate mainly in China, with exports extending its geographic reach internationally. The firm continues to develop innovative pharmaceutical excipients tailored to evolving industry needs while expanding production capabilities through substantial capital investments in new facilities and subsidiaries. This description is based on the latest publicly available corporate information as of late 2025.